(Q27012625)

language of work or name

1 reference

8 May 2013

3 references

2 October 2019

2 October 2020

3 references

2 October 2019

2 October 2020

14

1 reference

page(s)

49

1 reference

Creative Commons Attribution 2.0 Generic

copyright license

2 references

Europe PubMed Central

2 October 2019

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease

Europe PubMed Central

2 October 2020

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

β(2) -adrenoceptor agonists: current and future direction

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

An update on bronchodilators in Phase I and II clinical trials

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Pharmacology and therapeutics of bronchodilators

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

The Genuair® inhaler: a novel, multidose dry powder inhaler

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

The risks and benefits of indacaterol--the FDA's review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Night-time symptoms: a forgotten dimension of COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Novel bronchodilators for the treatment of chronic obstructive pulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Improving adherence with inhaler therapy in COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Indacaterol: in chronic obstructive pulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Impact of bronchodilator therapy on exercise tolerance in COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Emerging inhaled bronchodilators: an update

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Epidemiology and costs of chronic obstructive pulmonary disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

A review of the development of Respimat Soft Mist Inhaler

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Comparison of bronchodilatation produced by an anticholinergic (ipratropium bromide), a beta-2 adrenergic (fenoterol) and their combination in patients with chronic obstructive airway disease. An open trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651866

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

The functional impact of adding salmeterol and tiotropium in patients with stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Dry powder inhalers: which factors determine the frequency of handling errors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Inhaler mishandling remains common in real life and is associated with reduced disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-14-49

Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD

21 January 2018

1 reference

12 December 2020

Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis

1 reference

12 December 2020

The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group

1 reference

12 December 2020

In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group

1 reference

12 December 2020

Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients

1 reference

12 December 2020

The influence of age, diagnosis, and gender on proper use of metered-dose inhalers

1 reference

12 December 2020

Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group

1 reference

12 December 2020

For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base

1 reference

12 December 2020

Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study

1 reference

12 December 2020

Pooled clinical trial analysis of tiotropium safety

1 reference

12 December 2020

Identifiers

DOI

10.1186/1465-9921-14-49

1 reference

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1465-9921-14-49

1 reference

1 reference

PubMed publication ID

23651244

1 reference